by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
AusBioNEWSBOARD skills from her colleagues in accounting, putting her in the perfect position when the CEO role became available. Succession planning also played a part in Meera’s career positioning and it also meant that the company operations weren’t compromised by the staffing changes. Equally important in shaping Meera’s career, was her dedication to learning the art of Judo. Meera explains that her 30 years of Judo training has been instrumental in teaching timing and resilience and has been a strong and positive influence on Meera’s management style. In 2004, Meera and BresaGen faced their biggest challenge yet. The company’s business strategy at the time was to access finance in the USA. However, the financial climate post September 11, made it hard to find and secure money. Furthermore, the company’s lead product failed in clinical trials. The Board decided to surrender BresaGen into voluntary administration. At this time, Meera made a conscious decision to ensure the company survived and as a true leader she was driven by the responsibility to her team. With a skeleton workforce of 25 people, Meera, supported by Dr Stan Bastiras (CSO) and Dr Carol Senn (Production Manager), led the divestment and refinancing of the company. By the end of the following year, it was clear that Meera’s persistence and foresight paid off. The company’s purpose-built facility in Thebarton, SA now housed 50 staff and Meera’s team was positioned to consider any new opportunities. And just as the business cards were in print for BresaGen’s newest staff, Hospira ‘knocked’ on the company’s door. Meera’s motto is simple: be prepared by building incremental value. Whether she is training for her third dan black belt in Judo or moving up the corporate ladder, Meera is ready to move forward when the right opportunity arises. In many respects, this successful businesswoman, devoted mother and acknowledged industry leader, has achieved it all, including a multi-window corner office in the Thebarton, SA Bioscience precinct. 1 BRESA merged with another University of Adelaide spin-out company Reprotec and the resulting company was known as Bresatec. AusBiotech makes new appointment to team (L–R) Dr Anna Lavelle welcomes Stephen Pattillo, with AusBiotech’s Glenn Cross. AusBiotech is pleased to announce the appointment of Pattillo and Associates to work in NSW and boost awareness in the Asia Pacific region. Stephen Pattillo will work with AusBiotech’s NSW Industry Development Officer, Nicole Brackenridge, to support programming and services in the state. Stephen’s role — Representative, Asia Pacific and NSW, Business Development — will also seek to recruit conference participants for AusBiotceh and AusMedtech events from Asia. Stephen will continue to work with the state of Indiana in the US, and the US-ASEAN Business Council – and with existing business contacts and business associates. Stephen comes to AusBiotech as Managing Director of Pattillo and Associates Pty Ltd of Sydney, since 2002, with a wealth of experience in business development in Singapore and the US. Stephen spent eight years with the Washington-based lobbying firm, the US-ASEAN Business Council, working with the US Fortune 500 companies on their business strategies for Asia Pacific and in Singapore with member companies in Asia. While in Singapore, he served as Director, Southeast Asia for the States of Wisconsin, Maryland, Missouri and Indiana, facilitating business between these states and Southeast Asia. Stephen graduated from Duke University in the US and was first introduced to Australia and other parts of Asia/ Pacific during an exchange program with the University of New South Wales in 1993. Volume 19 • Number 2 • July 2009 Australasian BioTechnology 65